Analysts Have Conflicting Sentiments on These Healthcare Companies: Corvus Pharmaceuticals (CRVS), Vir Biotechnology (VIR) and Cooper Co (COO)
Vir Biotechnology Analyst Ratings
Morgan Stanley Maintains Vir Biotechnology(VIR.US) With Hold Rating, Maintains Target Price $15
Vir Biotechnology Analyst Ratings
A Quick Look at Today's Ratings for Vir Biotechnology(VIR.US), With a Forecast Between $13 to $28
Morgan Stanley Sticks to Its Hold Rating for Vir Biotechnology (VIR)
Analysts Offer Insights on Healthcare Companies: Passage Bio (PASG), Regeneron (REGN) and Vir Biotechnology (VIR)
Analysts Are Bullish on Top Healthcare Stocks: Neurocrine (NBIX), Vir Biotechnology (VIR)
Strategic Restructuring and Portfolio Diversification Solidify Buy Rating for Vir Biotechnology
Vir Biotechnology (VIR) Receives a Buy From TD Cowen
Vir Biotechnology Lowers FY24 Operating Expense Guidance >VIR
Morgan Stanley Maintains Equal-Weight on Vir Biotechnology, Raises Price Target to $15
Vir Biotechnology Analyst Ratings
Vir Biotechnology Analyst Ratings
Buy Rating Affirmed for Vir Biotechnology on Promising CHD and CHB Program Prospects
Buy Rating Affirmed for Vir Biotechnology on Promising HDV Program and Anticipated Trial Results
Analysts Offer Insights on Healthcare Companies: Talkspace (TALK), Vir Biotechnology (VIR) and Alvotech (ALVO)
Analysts' Top Healthcare Picks: Vir Biotechnology (VIR), Rocket Pharmaceuticals (RCKT)
Vir Biotechnology Analyst Ratings
JP Morgan Maintains Neutral on Vir Biotechnology, Raises Price Target to $12